Metabolex Secures Series D

Metabolex Inc., a Hayward, Calif.�based drug company focused on diabetes and other metabolic disorders, has raised $32 million in Series D funding. MPM BioEquities led the deal, and was joined by fellow new investors AllianceBernstein, Deerfield Management, T. Rowe Price. Return backers include Alta Partners, Bay City Capital, Biotech Turnaround Fund, Birchmere Ventures, Johnson & Johnson Development Corp., KBC Funds, Lombard Odier Darier Hentsch, Pictet Funds � Biotecho, Merlin Biomed, Novo Ventures, VantagePoint Ventures, Venrock Associates and Versant Ventures. Metabolex has raised around $196 million in total VC funding since 1996, including a 2003 financial restructuring.